Menu

For UK Healthcare Professionals

WHO TO CONSIDER FOR VOCABRIA + REKAMBYS?

Identifying suitable patients

Patients who express interest in less frequent dosing, or may benefit from Every 2-Month VOCABRIA + REKAMBYS

VOCABRIA injection is indicated, in combination with REKAMBYS injection, for the treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class.1 

When deciding who is right for VOCABRIA + REKAMBYS, it’s important to identify patients who can meet the clinical requirements and are ready to commit to the 2-month dosing schedule.1

Some patients will express interest and others may benefit from a discussion about any challenges they face with daily therapy such as fear of disclosure.2

  • Talking icon Patient need and commitment

    It is important to have a conversation to assess patient needs and willingness to commit to the VOCABRIA + REKAMBYS treatment schedule.

    • Has the patient expressed an interest in less-frequent dosing?
    • Could the patient benefit from long-acting treatment due to:
      • Concerns about disclosure?
      • Anxiety with staying adherent to oral ARVs?
      • The impact of daily medication as a reminder of their status and associated negative memories?
    • Is the patient able to commit to every 2-month visits?
    • Does the patient understand the importance of adhering to the schedule?

  • Board icon Main clinical requirements ¹,³

    • Virologically suppressed adults (HIV-1 RNA <50 copies/mL) 
    • No present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class
    • No contraindications or contraindicated concomitant therapies
    • VOCABRIA + REKAMBYS injection is not recommended during pregnancy unless the expected benefit justifies the potential risk to the foetus

Please see SmPC for complete list of clinical considerations for prescribing.

Find out what trial patients think about long-acting treatment

Icon for CTA Button

Patient testimonials

Hear what clinical trial patients say about their experience of long-acting therapy

ARV=antiretroviral; INI=integrase inhibitor; NNRTI=non-nucleoside reverse transcriptase inhibitor.

References:

  1. VOCABRIA Summary of Product Characteristics. ViiV Healthcare.
  2. de los Rios P, Okoli C, Castellanos E, et al. Physical, emotional, and psychosocial challenges associated with daily dosing of HIV medications and their impact on indicators of quality of life: findings from the Positive Perspectives Study. AIDS Behav. Published online ahead of print: October 7, 2020. doi: 10.1007/s10461-020-03055-1.
  3. REKAMBYS Summary of Product Characteristics. Janssen Healthcare.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

REKAMBYS (rilpivirine long acting injection), including the trademark is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV Healthcare group.

PM-GB-CBR-WCNT-210001v3 I April 2022

Prescribing Information

Report an adverse event

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.